- Products
- Flow Cytometry
- Biotheraputics Discovery
- Custom Services
- Bioanalytical Antibodies
- Tools and Resources
- Antibody Support
- Order Status
- Quick Order
- Support
Browsing Modes for Business Users
-
Create mode – the default mode when you create a requisition and PunchOut to Bio-Rad. You can create and edit multiple shopping carts
-
Edit mode – allows you to edit or modify an existing requisition (prior to submitting). You will be able to modify only the cart that you have PunchedOut to, and will not have access to any other carts
-
Inspect mode – when you PunchOut to Bio-Rad from a previously created requisition but without initiating an Edit session, you will be in this mode. You cannot modify any Cart contents
Anti-Durvalumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of durvalumab and biosimilars
Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody durvalumab (Imfinzi) using our range of ready-made antibodies.
- Recombinant antibodies specific to durvalumab
- TrailBlazer Antibody enabling site-directed conjugation and format switching
- Fully human surrogate positive control or calibrator
- Sequence-defined, well-characterized reagents with a secure supply
- Stringent quality control for batch-to-batch consistency
Table 1. Antibodies Specific to Durvalumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Durvalumab Inhibitory Type 1 |
TZA004 |
AbD41327ad |
Fab-F-Spy2-H1 |
3.6 |
PK bridging ELISA |
|
|
HCA359 |
AbD41310ia |
Human IgG1 |
4.8 |
ADA control |
Order HCA359 | |
|
HCA360 |
AbD41313ia |
Human IgG1 |
14 |
ADA bridging ELISA |
||
|
Durvalumab / PD-L1 Complex Specific Type 3 |
TZA002 |
AbD41240ad |
Fab-F-Spy2-H1 |
13 |
PK ELISA antigen capture format |
|
|
TZA002P |
AbD41240pap |
Fab2-FH-X22-HRP |
13 |
PK ELISA antigen capture format |
* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
Anti-Durvalumab Inhibitory Antibodies (Type 1)
Type 1 anti-durvalumab antibodies inhibit the binding of the monoclonal antibody drug durvalumab to its target, human programmed death-ligand 1 (PD-L1). They are ideal for the development of a PK bridging ELISA to measure free drug. In fully human IgG1 format, they are available in two affinities and are suitable for use as a surrogate positive control or reference standard in an ADA assay.
TrailBlazer Antibodies, clones AbD41240ad (TZA002) and AbD41327ad (TZA004), have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.
Anti-Durvalumab- PD-L1 Complex-Specific Antibody (Type 3)
The Type 3 antibody specifically recognizes the drug-target complex, detecting durvalumab only when it is bound to PD-L1. It is suitable as a detection antibody in a PK antigen capture assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Durvalumab PK bridging ELISA using antibodies TZA004 and HCA360
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
PK Antigen Capture
Fig. 2. Durvalumab PK Antigen Capture ELISA using antibody TZA002.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
ADA Bridging ELISA
ADA bridging ELISA: HCA359 or HCA360 monoclonal antibody as surrogate positive control or calibrator
Fig. 3. Durvalumab ADA bridging ELISA using antibody HCA359 or HCA360.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.